Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03332459




Registration number
NCT03332459
Ethics application status
Date submitted
16/10/2017
Date registered
6/11/2017
Date last updated
13/04/2021

Titles & IDs
Public title
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Scientific title
A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Secondary ID [1] 0 0
2016-002095-26
Secondary ID [2] 0 0
CR108375
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lumicitabine
Treatment: Drugs - Placebo

Experimental: Lumicitabine - Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.

Placebo Comparator: Placebo - Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.


Treatment: Drugs: Lumicitabine
Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.

Treatment: Drugs: Placebo
Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Asthma After Respiratory Syncytial Virus (RSV) Infection
Timepoint [1] 0 0
Up to 2 years
Primary outcome [2] 0 0
Percentage of Wheezing Days in Participants Within the First 2 Years After RSV Infection
Timepoint [2] 0 0
Up to 2 years
Secondary outcome [1] 0 0
Percentage of Wheezing Days in Participants Per Month After RSV Infection
Timepoint [1] 0 0
Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Secondary outcome [2] 0 0
Number of Wheezing Episodes in Participants Per Month After the RSV Infection
Timepoint [2] 0 0
Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Secondary outcome [3] 0 0
Number of Participants With Reportable Adverse Events (AEs)
Timepoint [3] 0 0
Up to 2 years
Secondary outcome [4] 0 0
Number of Participants With Serious Adverse Events (SAEs)
Timepoint [4] 0 0
Up to 2 years
Secondary outcome [5] 0 0
Number of Respiratory Infections Per Participant
Timepoint [5] 0 0
Up to 2 years
Secondary outcome [6] 0 0
Number of Participants With Medical Encounters
Timepoint [6] 0 0
Up to 2 years

Eligibility
Key inclusion criteria
- Male or female infants and children who were previously randomized in study
64041575RSV2004 for the treatment of respiratory syncytial virus (RSV) infection and
who completed the planned course of the study drug and the last study-related visit of
study 64041575RSV2004

- The participant's legally acceptable representative must sign an informed consent form
(ICF) indicating that he or she understands the purpose of, and procedures required
for, the study and is willing for the participant to participate in the study
Minimum age
56 Days
Maximum age
39 Months
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- The participants legally acceptable representative, i.e, parent/legal
guardian/caregiver, is not able to maintain reliable communication with the
investigator

- Any condition for which, in the opinion of the investigator, participation would not
be in the best interest of the participant (example, compromise the well-being) or
that could prevent, limit, or confound the protocol-specified assessments

Study design
Purpose of the study
Other
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/01/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/04/2020
Sample size
Target
Accrual to date
Final
7
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Japan
State/province [1] 0 0
Fukuyama
Country [2] 0 0
Japan
State/province [2] 0 0
Hirosaki
Country [3] 0 0
Japan
State/province [3] 0 0
Niigata
Country [4] 0 0
Japan
State/province [4] 0 0
Oita

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this long-term follow-up (LTFU) study is to evaluate the incidence of the
clinical diagnosis of asthma and the frequency of wheezing in infants and children with
respiratory syncytial virus (RSV) infection who were treated with (lumicitabine or placebo)
and have completed their last planned study-related visit in a feeding Phase 2 study
(64041575RSV2004).
Trial website
https://clinicaltrials.gov/ct2/show/NCT03332459
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03332459